290 related articles for article (PubMed ID: 1829918)
1. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Mandelli F; Petti MC; Ardia A; Di Pietro N; Di Raimondo F; Ganzina F; Falconi E; Geraci E; Ladogana S; Latagliata R
Eur J Cancer; 1991; 27(6):750-5. PubMed ID: 1829918
[TBL] [Abstract][Full Text] [Related]
2. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
4. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
[TBL] [Abstract][Full Text] [Related]
5. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.
Resegotti L
Leukemia; 1992; 6 Suppl 2():72-5. PubMed ID: 1578948
[TBL] [Abstract][Full Text] [Related]
7. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Vogler WR; Velez-Garcia E; Weiner RS; Flaum MA; Bartolucci AA; Omura GA; Gerber MC; Banks PL
J Clin Oncol; 1992 Jul; 10(7):1103-11. PubMed ID: 1607916
[TBL] [Abstract][Full Text] [Related]
8. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
[TBL] [Abstract][Full Text] [Related]
9. Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Beksaç M; Arslan O; Koç H; Akan H; Ilhan O; Arat M; Ozcan M; Gürman G; Konuk N; Uysal A
Med Oncol; 1998 Sep; 15(3):183-90. PubMed ID: 9819795
[TBL] [Abstract][Full Text] [Related]
10. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
[TBL] [Abstract][Full Text] [Related]
11. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M
Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986
[TBL] [Abstract][Full Text] [Related]
12. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
14. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
[TBL] [Abstract][Full Text] [Related]
15. Selective use of daunorubicin for remission-induction chemotherapy in acute non-lymphoblastic leukemia.
Shaikh BS; Dougherty JB; Hamilton RW; Ballard JO; Patel SB; Gevirtz NR; Eyster ME
Cancer; 1980 Oct; 46(8):1731-4. PubMed ID: 6932996
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
[TBL] [Abstract][Full Text] [Related]
17. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
18. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
19. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Berman E; Heller G; Santorsa J; McKenzie S; Gee T; Kempin S; Gulati S; Andreeff M; Kolitz J; Gabrilove J
Blood; 1991 Apr; 77(8):1666-74. PubMed ID: 2015395
[TBL] [Abstract][Full Text] [Related]
20. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
